{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:47:39Z","timestamp":1788886059030,"version":"build-2803163510"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Medicine and Surgery"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.amsu.2020.10.024","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T01:26:33Z","timestamp":1602897993000},"page":"31-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report"],"prefix":"10.1097","volume":"60","author":[{"given":"Teppei","family":"Kamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6807-1735","authenticated-orcid":false,"given":"Shinya","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Nakaseko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Ohdaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.amsu.2020.10.024_bib1","doi-asserted-by":"crossref","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","article-title":"Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Fizazi","year":"2015","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.amsu.2020.10.024_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/bjc.2012.516","article-title":"Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis","volume":"108","author":"Lee","year":"2013","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.amsu.2020.10.024_bib3","author":"Nccn clinical practice guidelines in oncology"},{"issue":"7","key":"10.1016\/j.amsu.2020.10.024_bib4","doi-asserted-by":"crossref","first-page":"807","DOI":"10.6004\/jnccn.2018.0062","article-title":"NCCN guidelines insights: non-small cell lung cancer, version 5.2018","volume":"16","author":"Ettinger","year":"2018","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"22","key":"10.1016\/j.amsu.2020.10.024_bib5","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.amsu.2020.10.024_bib6","article-title":"The SCARE 2018 statement: updating consensus surgical CAse report(SCARE) guidelines","volume":"60","author":"Agha","year":"2018","journal-title":"Int. J. Surg."},{"issue":"2","key":"10.1016\/j.amsu.2020.10.024_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Canc."},{"issue":"1","key":"10.1016\/j.amsu.2020.10.024_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clon.2006.09.009","article-title":"A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network","volume":"19","author":"Shaw","year":"2007","journal-title":"Clin. Oncol."},{"issue":"11","key":"10.1016\/j.amsu.2020.10.024_bib9","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/cncr.22300","article-title":"Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site","volume":"107","author":"Seve","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.amsu.2020.10.024_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.critrevonc.2012.03.003","article-title":"Management of \u2018\u2018unfavourable\u2019\u2019 carcinoma of unknown primary site: synthesis of recent literature","volume":"84","author":"Amela","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.amsu.2020.10.024_bib11","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ctrv.2009.05.005","article-title":"Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis","volume":"35","author":"Golfinopoulos","year":"2009","journal-title":"Canc. Treat Rev."},{"key":"10.1016\/j.amsu.2020.10.024_bib12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/PPO.0b013e3181c6aa89","article-title":"Paclitaxel\/carboplatin\/etoposide versus gemcitabine\/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized phase III Sarah Cannon Research Consortium Trial","volume":"16","author":"Hainsworth","year":"2010","journal-title":"Canc. J."},{"key":"10.1016\/j.amsu.2020.10.024_bib13","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1200\/JCO.2003.12.104","volume":"21","author":"Culine","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.amsu.2020.10.024_bib14","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S1470-2045(08)70151-7","article-title":"Carcinoma of unknown primary with a colon-cancer profile: changing paradigm and emerging definitions","volume":"9","author":"Varadhachary","year":"2008","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.amsu.2020.10.024_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175679","article-title":"Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: a systematic review of recently published studies","volume":"12","author":"Davies","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.amsu.2020.10.024_bib16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fmed.2017.00004","article-title":"Historical evolution of second-line therapy in non-small cell lung cancer","volume":"4","author":"Lazzari","year":"2017","journal-title":"Front. Med."},{"key":"10.1016\/j.amsu.2020.10.024_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ."},{"issue":"7","key":"10.1016\/j.amsu.2020.10.024_bib18","article-title":"Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells","volume":"6","author":"Wang","year":"2017","journal-title":"OncoImmunology"},{"issue":"10","key":"10.1016\/j.amsu.2020.10.024_bib19","doi-asserted-by":"crossref","DOI":"10.4161\/onci.27025","article-title":"Effects of conventional therapeutic interventions on the number and function of regulatory T cells","volume":"2","author":"Roselli","year":"2013","journal-title":"OncoImmunology"},{"key":"10.1016\/j.amsu.2020.10.024_bib20","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1172\/JCI43656","article-title":"Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice","volume":"121","author":"Lesterhuis","year":"2011","journal-title":"J. Clin. Invest."}],"container-title":["Annals of Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2049080120303782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2049080120303782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T16:06:23Z","timestamp":1677081983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2049080120303782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":20,"alternative-id":["S2049080120303782"],"URL":"https:\/\/doi.org\/10.1016\/j.amsu.2020.10.024","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report","name":"articletitle","label":"Article Title"},{"value":"Annals of Medicine and Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amsu.2020.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.","name":"copyright","label":"Copyright"}]}}